Clinical trial
Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic…
NCT02553317 · Ablynx, a Sanofi company, Industry · Completed
Key facts
| NCT number | NCT02553317 |
|---|---|
| Title | Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura |
| Official title | A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura |
| Acronym | HERCULES |
| Lead sponsor | Ablynx, a Sanofi company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acquired Thrombotic Thrombocytopenic Purpura |
| Intervention type | Biological |
| Interventions | Caplacizumab, Placebo |
| Enrollment | 145 |
| Start date | Nov 1, 2015 |
| Primary completion | Aug 1, 2017 |
| Completion | Aug 1, 2017 |
| First posted | Sep 17, 2015 |
| Last update posted | Apr 5, 2023 |
| Countries | Australia, Austria, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Netherlands, Spain and 4 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: